Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 34 citing articles:

Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Katherine McMahan, Frank Wegmann, Malika Aïd, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 385-391
Open Access | Times Cited: 49
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens
Farokh Dotiwala, Arun Kumar Upadhyay
Vaccines (2023) Vol. 11, Iss. 10, pp. 1585-1585
Open Access | Times Cited: 33
COVID-19 vaccines: Immune correlates and clinical outcomes
Shant H. Mahrokhian, Lisa H. Tostanoski, Samuel J. Vidal, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 12
Molecular basis of Ad5-nCoV vaccine-induced immunogenicity
Dongyang Dong, Yutong Song, Shipo Wu, et al.
Structure (2025)
Open Access | Times Cited: 1
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
Stefan Slamanig, Irene González‐Domínguez, Lauren A Chang, et al.
EBioMedicine (2024) Vol. 105, pp. 105185-105185
Open Access | Times Cited: 8
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
Siyue Jia, Zundong Yin, Hongxing Pan, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
Rick Heida, Henderik W. Frijlink, Wouter L.J. Hinrichs
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 13
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Kevin J. Selva, Pradhipa Ramanathan, Ebene R. Haycroft, et al.
JCI Insight (2023) Vol. 8, Iss. 18
Open Access | Times Cited: 11
Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis
Song Gao, Rong Li, Meng-Qun Cheng
Journal of Medical Virology (2024) Vol. 96, Iss. 4
Open Access | Times Cited: 4
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Thermostabilization of a model viral-vectored oral thin film vaccine
Annika Yardy, I. Wang, Yva Rasco, et al.
International Journal of Pharmaceutics (2025), pp. 125662-125662
Open Access
Evaluation of antibody responses in healthy individuals receiving SARS-CoV-2 inactivated vaccines
Ziyu Liu, Liyan Cai, Man Xing, et al.
Biosafety and Health (2024) Vol. 6, Iss. 3, pp. 153-164
Open Access | Times Cited: 3
Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle
Jinghan Xu, Busen Wang, Zhenghao Zhao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial
Jiawei Xu, Busen Wang, Ping Gao, et al.
Emerging Microbes & Infections (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
Keda Chen, Ling Zhang, Zhongbiao Fang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development
Tuksin Jearanaiwitayakul, Panya Sunintaboon, Anuwat Kittiayuwat, et al.
Vaccine (2024) Vol. 42, Iss. 17, pp. 3664-3673
Open Access | Times Cited: 2
Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial
Huan Zhou, Huijuan Zheng, Yucai Peng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses
Gina M. Borgo, Rachel L. Rutishauser
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 6, pp. 331-341
Open Access | Times Cited: 5
A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV
Zhe Zhang, Xiangyang Chi, Guan-Ying Zhang, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals
Najwa D. Aljehani, Levi Tamming, Muhammad Yasir Khan, et al.
mBio (2024)
Closed Access | Times Cited: 1
Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges
Júlio Croda
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 10, pp. 1099-1100
Open Access | Times Cited: 3
A next-generation inhalable dry powder COVID vaccine
Zhou Xing, Mangalakumari Jeyanathan
Nature (2023) Vol. 624, Iss. 7992, pp. 532-534
Closed Access | Times Cited: 3
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China
Hu-Dachuan Jiang, Pengfei Jin, Xiling Guo, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1815-1815
Open Access | Times Cited: 1
Robust memory humoral immune response to SARS-CoV-2 in the tonsils of adults and children
Tarfa Altorki, Rwaa H. Abdulal, Bandar A. Suliman, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top